Navigation Links
MIGENIX to Add 600mg Daily Celgosivir Dose to Phase II Viral Kinetics Study
Date:1/31/2008

applicable securities laws in Canada, (collectively referred to as "forward-looking statements"). Statements, other than statements of historical fact, are forward-looking statements and include, without limitation, statements regarding our strategy, future operations, timing and completion of clinical trials, prospects, plans and objectives of management. The words "anticipates", "believes", "budgets", "could", "estimates", "expects", "forecasts", "intends", "may", "might", "plans", "projects", "schedule", "should", "will", "would" and similar expressions are often intended to identify forward-looking statements, which include underlying assumptions, although not all forward-looking statements contain these identifying words. By their nature, forward-looking statements involve numerous assumptions, known and unknown risks and uncertainties, both general and specific, that contribute to the possibility that the predictions, forecasts, projections and other things contemplated by the forward-looking statements will not occur.

Although our management believes that the expectations represented by such forward-looking statements are reasonable, there is significant risk that the forward-looking statements may not be achieved, and the underlying assumptions thereto will not prove to be accurate. Forward-looking statements in this news release include, but are not limited to, statements concerning our expectations for: increasing the celgosivir dose to 600mg being an important development step for the optimization and advancement of celgosivir; our plans to add approximately six patients at 600mg dose in the celgosivir Phase II viral kinetics study and having results from the study in the third quarter 2008; Cadence Pharmaceuticals completing enrollment in the CLIRS trial in the second quarter of 2008, with results available in the second half of 2008; and Cutanea Life Sciences' plans to advance omiganan for the treatment of rosacea to Phase III clinical developme
'/>"/>

SOURCE MIGENIX Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related biology technology :

1. MIGENIX Reports Second Quarter Fiscal Year 2008 Financial Results
2. MIGENIX Second Fiscal Quarter 2008 Financial Results Conference Call & Webcast Notification
3. MIGENIX to Present at the Acumen BioFin Rodman & Renshaw 9th Annual Healthcare Conference
4. MIGENIX Reports First Quarter Fiscal Year 2008 Financial Results
5. MIGENIX to Present Positive Celgosivir Viral Resistance Data at International HCV Meeting
6. MIGENIX First Fiscal Quarter 2008 Financial Results Conference Call & Webcast Notification
7. Dey L.P. and Critical Therapeutics Launch Twice-Daily ZYFLO CR(TM) (Zileuton) Extended-Release Tablets for the Chronic Treatment of Asthma
8. Cephalon, Inc. Announces Agreement to Acquire AMRIX, A Once-Daily Extended-Release Muscle Relaxant
9. Oncolytics Biotech Inc. Proceeds to Full Enrolment in U.S. Phase II Sarcoma Clinical Trial
10. Phase 1 Studies Show Promise of QuatRxs Novel Compound, Sobetirome, for Lowering LDL Cholesterol Levels
11. Surface Logix Achieves Objectives With SLx-4090 in Phase 2a Clinical Trial
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/2/2015)... Israel , September 2, 2015 ... announced the intent of the National Institute of Allergy and ... Health (NIH) within the Department of Health and Human Services ... held in the United States in ... BiondVax,s universal flu vaccine candidate, Multimeric-001 (M-001), as a primer ...
(Date:9/2/2015)... California (PRWEB) , ... September 02, 2015 , ... ... a critical demand to aid high-risk surgeries. From vital sign monitoring in ICU ... by Intel technology enables surgeon to make real-time clinical decisions with simultaneous access ...
(Date:9/2/2015)... ... 2015 , ... Temarry Recycling's new $100,000 waste to energy ... and continue to contribute to the sustainability of our natural resources. , Waste ... has been operating at their Mexico facility, Recicladora Temarry, for the last 7 ...
(Date:9/2/2015)... ... September 02, 2015 , ... ... life science research, today unveiled Genedata Screener ® version 13.0 at ELRIG ... screening brings to market a rich set of new capabilities. Screener now supports ...
Breaking Biology Technology:BiondVax Announces Intent to Launch a Phase 2 Trial in the United States in Collaboration with the U.S. National Institutes of Health 2BiondVax Announces Intent to Launch a Phase 2 Trial in the United States in Collaboration with the U.S. National Institutes of Health 3Surgical Workstation Powered by 6th Gen. Intel® Core™ Skylake Processors 2Surgical Workstation Powered by 6th Gen. Intel® Core™ Skylake Processors 3Temarry Recycling’s New $100,000 Waste to Energy Renovation 2New Genedata Screener 13.0 with Support for High Throughput Flow Cytometry and DMPK Unveiled at ELRIG 2New Genedata Screener 13.0 with Support for High Throughput Flow Cytometry and DMPK Unveiled at ELRIG 3New Genedata Screener 13.0 with Support for High Throughput Flow Cytometry and DMPK Unveiled at ELRIG 4
... Wilson , an 18-year GE veteran, was promoted to president ... May to replace Gregory Lucier, who left to become CEO ... most of GE Medical's monitoring systems . , ,It's a ... growth opportunity (GE Medical is about $9 billion and produced ...
... - With Sony set to take over Sonic Foundrys desktop ... go from here? Two words: Mediasite Live. , ,Sonic ... audio conferencing market by enhancing web conferencing with Mediasite Live. ... great opportunity for the company to go forward because there ...
... employee scheduling and management products. The company was the ... Suite Scheduler, a former nurse manager frustrated with the ... facility. , ,Suite Scheduler products are able to improve ... of the time to create and manage employee schedules ...
Cached Biology Technology:CEO Wilson Defines GE's Health-IT Customer 2CEO Wilson Defines GE's Health-IT Customer 3CEO Wilson Defines GE's Health-IT Customer 4Sonic Foundry: What's Next? 2Scheduling made easy with Suite Scheduler 2Scheduling made easy with Suite Scheduler 3
(Date:8/5/2015)... , Aug. 5, 2015 The biosensors market ... in applications, penetration into newer sectors, and development of ... global biosensors space has seen the entry of multiple ... so far. (Photo - http://photos.prnewswire.com/prnh/20150805/255570 ) ... Analysis of the Global Biosensors Market ( ...
(Date:8/3/2015)... , Aug. 3, 2015 Synaptics, Inc. (Nasdaq: ... solutions, today announced that members of the executive management ... Pacific Crest Global Technology Leadership Forum on Tuesday, August ... will be held at the Sonnenalp Resort in ... presentation may include forward-looking information. An audio webcast of ...
(Date:7/31/2015)... de 2015 A 10 a. Conferência ... pela BGI de 22-25 de outubro de 2015, em ... conferência está celebrando seu 10 o. aniversário este ano. ... uma das reuniões mais influentes do mundo no ramo ... entusiastas e prazerosos. A ICG-10 se ...
Breaking Biology News(10 mins):Innovative Biosensors Incite Use in Non-Traditional Applications 2Innovative Biosensors Incite Use in Non-Traditional Applications 3Innovative Biosensors Incite Use in Non-Traditional Applications 4A 10a. Conferência Internacional sobre Genômica (ICG-10) será em outubro 2A 10a. Conferência Internacional sobre Genômica (ICG-10) será em outubro 3
... work, home or elsewhere results in a disproportionate rise ... University of Nottingham researchers have found. , A new ... Heart Association, measured the level of cotinine in participants' ... to second-hand smoke. Cotinine is the major metabolite of ...
... Trek: The Next Generation," Geordi La Forge is a ... special implants in his eyes. While the Star Trek ... the 21st century may not have to wait that ... a University of Missouri-Columbia veterinary ophthalmologist, has been working ...
... with a knowledge of the properties and actions of enzymes, ... anti-cancer drugs originally isolated from blue-green algae. , This ... of the promising drugs for use in clinical trials. ... January issue of the journal ACS Chemical Biology, a scientific ...
Cached Biology News:Indicators for risk of heart disease are higher in passive smokers 2Indicators for risk of heart disease are higher in passive smokers 3MU researcher placing eye implants in cats to help humans see 2Turning green gunk to gold, anti-cancer gold 2
Zebrafish Ephrin-B2 Biotinylated Affinity Purified PAb...
...
Donor Goat Serum...
GeneRacer is an advanced RACE (rapid amplification of cDNA ends) technique that improves the efficiency of amplifying full-length 5' and 3' cDNA ends. With the GeneRacer Kit you can:...
Biology Products: